CA13650/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
1986	1
1995	2
1996	2
1997	1
1998	5
1999	2
2000	2
2001	6
2002	4
2003	9
2004	13
2005	7
2006	9
2007	4
2008	2
2009	9
2010	8
2011	8
2012	4
2013	10
2014	7
2015	6
2016	1
2017	1
2025	0

1

Phase III study of the Eastern Cooperative Oncology Group (ECOG 2597): induction chemotherapy followed by either standard thoracic radiotherapy or hyperfractionated accelerated radiotherapy for patients with unresectable stage IIIA and B non-small-cell lung cancer.

Belani CP, Wang W, Johnson DH, Wagner H, Schiller J, Veeder M, Mehta M; Eastern Cooperative Oncology Group. Belani CP, et al. J Clin Oncol. 2005 Jun 1;23(16):3760-7. doi: 10.1200/JCO.2005.09.108. Epub 2005 Apr 18. J Clin Oncol. 2005. PMID: 15837967 Review.

2

Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003).

Dhodapkar MV, Jacobson JL, Gertz MA, Rivkin SE, Roodman GD, Tuscano JM, Shurafa M, Kyle RA, Crowley JJ, Barlogie B. Dhodapkar MV, et al. Blood. 2001 Jul 1;98(1):41-8. doi: 10.1182/blood.v98.1.41. Blood. 2001. PMID: 11418461 Free article. Clinical Trial.

3

Topotecan in previously treated advanced urothelial carcinoma: an ECOG phase II trial.

Witte RS, Manola J, Burch PA, Kuzel T, Weinshel EL, Loehrer PJ Sr. Witte RS, et al. Invest New Drugs. 1998;16(2):191-5. doi: 10.1023/a:1006159525793. Invest New Drugs. 1998. PMID: 9848585 Clinical Trial.

4

Thalidomide-prednisone maintenance following autologous stem cell transplant for multiple myeloma: effect on thrombin generation and procoagulant markers in NCIC CTG MY.10.

Kovacs MJ, Davies GA, Chapman JA, Bahlis N, Voralia M, Roy J, Kouroukis CT, Chen C, Belch A, Reece D, Zhu L, Meyer RM, Shepherd L, Stewart KA. Kovacs MJ, et al. Br J Haematol. 2015 Feb;168(4):511-7. doi: 10.1111/bjh.13176. Epub 2014 Oct 10. Br J Haematol. 2015. PMID: 25302852 Clinical Trial.

5

A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale.

Eton DT, Cella D, Yost KJ, Yount SE, Peterman AH, Neuberg DS, Sledge GW, Wood WC. Eton DT, et al. J Clin Epidemiol. 2004 Sep;57(9):898-910. doi: 10.1016/j.jclinepi.2004.01.012. J Clin Epidemiol. 2004. PMID: 15504633

6

Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma.

Kumar S, Zhang L, Dispenzieri A, Van Wier S, Katzmann JA, Snyder M, Blood E, DeGoey R, Henderson K, Kyle RA, Bradwell AR, Greipp PR, Rajkumar SV, Fonseca R. Kumar S, et al. Leukemia. 2010 Aug;24(8):1498-505. doi: 10.1038/leu.2010.128. Epub 2010 Jun 3. Leukemia. 2010. PMID: 20520636 Free PMC article. Clinical Trial.

7

Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281.

Sun W, Lipsitz S, Catalano P, Mailliard JA, Haller DG; Eastern Cooperative Oncology Group. Sun W, et al. J Clin Oncol. 2005 Aug 1;23(22):4897-904. doi: 10.1200/JCO.2005.03.616. J Clin Oncol. 2005. PMID: 16051944 Clinical Trial.

8

Brief physician-initiated quit-smoking strategies for clinical oncology settings: a trial coordinated by the Eastern Cooperative Oncology Group.

Schnoll RA, Zhang B, Rue M, Krook JE, Spears WT, Marcus AC, Engstrom PF. Schnoll RA, et al. J Clin Oncol. 2003 Jan 15;21(2):355-65. doi: 10.1200/JCO.2003.04.122. J Clin Oncol. 2003. PMID: 12525530 Clinical Trial.

9

Comparison of 5-fluorouracil alone, 5-fluorouracil with levamisole, and 5-fluorouracil with hepatic irradiation in the treatment of patients with residual, nonmeasurable, intra-abdominal metastasis after undergoing resection for colorectal carcinoma.

Witte RS, Cnaan A, Mansour EG, Barylak E, Harris JE, Schutt AJ. Witte RS, et al. Cancer. 2001 Mar 1;91(5):1020-8. Cancer. 2001. PMID: 11251955 Clinical Trial.

10

Randomized phase II trial of paclitaxel plus carboplatin or gemcitabine plus cisplatin in Eastern Cooperative Oncology Group performance status 2 non-small-cell lung cancer patients: ECOG 1599.

Langer C, Li S, Schiller J, Tester W, Rapoport BL, Johnson DH; Eastern Cooperative Oncology Group. Langer C, et al. J Clin Oncol. 2007 Feb 1;25(4):418-23. doi: 10.1200/JCO.2005.04.9452. J Clin Oncol. 2007. PMID: 17264337 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

110 results

Results by year

Search Page

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

110 results

Results by year